# Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment

> **NCT01688882** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Bullous Pemphigoid

## Interventions

- **DRUG:** QGE031
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01688882
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** This study was stopped after Part 1 completed and was terminated because the predefined criteria of efficacy was not reached ( \>50% better then placebo)
- **Last updated:** 2016-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01688882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01688882, "Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01688882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*